Salpingectomy before assisted reproductive technologies: a systematic literature review by unknown
REVIEW Open Access
Salpingectomy before assisted reproductive
technologies: a systematic literature review
Marco Noventa1, Salvatore Gizzo1, Carlo Saccardi1, Shara Borgato1, Amerigo Vitagliano1, Michela Quaranta2,
Pietro Litta1, Michele Gangemi1, Guido Ambrosini1, Donato D’Antona1 and Stefano Palomba3*
Abstract
Salpingectomy is largely used in case of hydrosalpinx in infertile women scheduled for assisted reproductive
technologies (ART), whereas there is no consensus on its role in absence of hydrosalpinx. The current is a
systematic literature review to collate all available evidence regarding salpingectomy as fertility enhancement
procedure before ART in infertile patients. Our primary endpoint was to assess the impact of the surgical
procedure on ovarian reserve, and secondary outcomes were to evaluate its benefits and harms on ART
outcomes. We identified 29 papers of which 16 reporting data on the impact of tubal surgery on ovarian reserve
and 24 (11 previously included) on ART outcomes. Available data suggested an absence of variation in ovarian
reserve markers after unilateral salpingectomy while contradictory results were reported for bilateral surgery.
Considering ART outcomes, data reported a significant improvement in ongoing pregnancy/live-birth rate in
treated subjects without significant reduction in ovarian response to gonadotropin stimulation. In case of tubal
disease, a surgical approach based on unilateral salpingectomy may be considered safe, without negative effects
on ovarian reserve and ovarian response to controlled ovarian stimulation whilst having a positive effect on
pregnancy rate. Data regarding bilateral salpingectomy and ovarian reserve are conflicting. Further trials are
needed to confirm both the benefits of salpingectomy before ART and the safety of bilateral salpingectomy on
ovarian reserve, and to clarify the role of uni- or bilateral surgery in case of tubal blockage without hydrosalpinx.
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Background
Outstanding advances in technology have made in vitro
fertilization (IVF) an everyday treatment for infertility.
The rapid development of IVF and embryo transfer (ET)
has seen assisted reproduction proposed as a valid choice
for women affected by different type of infertility ranging
from aging related problems [1–3] to organic pathologies
such as tubal factor [4–6].
Assisted reproduction disregards the physiological
role of salpinx during reproduction and has thus gener-
ated a minimal or absent interest for tubal diseases in
women referred to IVF, a fact confirmed by the paucity
of evidences available on this topic if compared with a
large amount of literature continuously produced on
ovarian response, oocytes/embryo quality and endomet-
rial factor. However, it has been demonstrated that, in
patients suffering from hydrosalpinx and tubal factor
infertility, the overall success of IVF is lower than
expected due to implantation failure, miscarriage and
ectopic pregnancy [6, 8].
These findings raised speculations regarding the detri-
mental role of salpinx fluid by both directly by contaminat-
ing the uterine cavity (reduction in embryo implantation)
[9–11] and/or indirectly by exerting a toxic effect on the
implanted embryo (impairment in embryo development)
[12, 13]. This led the United Kingdom’s National institute
of Health and Clinical Excellence guidelines (NICE) to rec-
ommend laparoscopic salpingectomy before assisted repro-
ductive technologies (ART) in case of signs or suspicions
of hydrosalpinx [14]. These Guidelines are also supported
by data analyzed in a recent Cochrane review emphasizing
a superior pregnancy rate when patients with tubal disease
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underwent laparoscopic salpingectomy (or at least tubal
occlusion) prior to IVF treatments [15].
While salpingectomy before ART is universally recom-
mended in case of evident hydrosalpinx [4, 5, 16, 17],
no clear recommendations are available for the man-
agement of the wide spectrum of tubal pathologies of
varying severity such as slight tubal dilatation (uni- or
bilateral), previous tubal abortion and negative tubal
patency test without hydrosalpinx. No clear recommen-
dations regarding the surgical management of varying
degrees of hydrosalpinx nor of unilateral hydrosalpinx
with non-patent contralateral tube are available in the
literature. The lack of accepted evidences regarding the
potential detrimental effects of salpingectomy on ovar-
ian reserve further complicate the determination of the
most appropriate management for tubal disease before
ART [18–20].
Based on these considerations, we performed a system-
atic literature review of all available evidence in order to
summarize the actual benefits/harms of salpingectomy be-
fore ART in patients with and without hydrosalpinx.
Methods
A systematic literature search (English and French writ-
ten literature) was conducted by electronic search of
public databases MEDLINE, EMBASE, Science-Direct
and the Cochrane library. We collected evidences dat-
ing from 1998 till 2015. This systematic review was
conducted according to the Preferred Reporting Items
for Systematic reviews and Meta-Analysis (PRISMA)
guidelines. All longitudinal studies which evaluated
ovarian reserve and subsequent ART outcomes follow-
ing tubal surgery for enhancing fertility (i.e. unilateral
and/or bilateral salpingectomy, tubal occlusion, etc.)
were identified and analyzed. A manual search of the
reference lists of the included studies and review arti-
cles was successively performed. All references of the
retrieved studies were also reviewed to avoid overlook-
ing relevant publications.
Primary outcome was to evaluate whether tubal sur-
gery may have detrimental effects on ovarian reserve.
Serum concentration of follicle stimulating hormone
(FSH) and/or anti-Müllerian hormone (AMH) and/or
antral follicle count (AFC) were considered as markers
of ovarian reserve. Differences in ovarian reserve tests
from baseline (pre-surgery) or in comparison with un-
treated (no surgery) arm were considered and dis-
cussed. Secondary outcome was to evaluate potential
effects (benefits and harms) of tubal surgery on ovarian
response in controlled stimulation cycles.
Search strategy
The key search terms included: “unilateral/bilateral sal-
pingectomy” [Mesh] and “ovarian reserve” OR “AFC”
OR “AMH” OR “FSH” OR “ART outcome” OR “IVF
outcome”.
The selection of included studies was based on the avail-
ability of baseline AFC and/or baseline serum concentra-
tion of AMH and FSH in patients treated by unilateral/
bilateral salpingectomy (laparoscopy/laparotomy) for be-
nign gynecological disease. We also included all studies
which reported in detail ART outcomes in patients with a
history of unilateral/bilateral salpingectomy (laparoscopy/
laparotomy) compared to untreated controls.
Titles and abstracts from electronic searches were
scrutinized and reviewed by two authors independently
(M.N; S.B) and full manuscripts and relative citation lists
were analyzed by a third reviewer (S.G) with the scope
of retrieving any omitted articles and selection of manu-
scripts by application of inclusion criteria.
Available data independently according to the subse-
quent topics: “Modifications in basal AMH and FSH
after salpingectomy”, “ART after salpingectomy”, “ART
outcomes following salpingectomy” were analyzed
qualitatively.
Inclusion and exclusion criteria
Studies were considered eligible if they satisfied the fol-
lowing criteria: i) longitudinal prospective, randomized
trial or retrospective studies; ii) study population com-
prised exclusively of women of reproductive age under-
going unilateral or bilateral salpingectomy for benign
gynecological disease, iii) presence of a control group ei-
ther consisting of healthy matched controls or the same
subjects prior to surgery; iv) ovarian reserve must be
described by basal serum value of AMH and/or FSH
and/or AFC for the entire sample; v) ART outcome must
be described by at least one of the following, number of
oocytes retrieved and/or number of obtained embryos
and/or pregnancy rate. Exclusion criteria were consid-
ered: reviews and case report, duplicated data, and longi-
tudinal studies referring to intrauterine insemination.
Results
The systematic literature search based on our pre-defined
key search items yielded a total of 147 potentially relevant
papers. Out of 147 only 29 met the inclusion criteria
(Fig. 1) [1–13, 16–31]. A full report regarding authors,
study design, sample size, type of surgical procedure (uni-
lateral/bilateral salpingectomy), epidemiological features,
surgical indications and years from surgery is illustrated in
detail in Table 1.
The majority of patients underwent a laparoscopic
surgical procedure (Table 1). The surgical indication
was either hydrosalpinx or ectopic pregnancy in nearly
all patients considered; only one manuscript included
patients with salpingectomy due to tube-ovarian abscess
[28]. Descriptive reports regarding baseline serum FSH
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and AMH serum values and AFC of patients included in
the review are described in detail in Table 2. Descriptive
reports concerning ART outcome [in particular: estradiol
(E2) at ovulation induction, stimulation length, number of
oocytes retrieved, obtained embryos, transferred embryos,
implantation rate, clinical pregnancy rate, ongoing preg-
nancy rate] are reported in detail in Table 3.
Effect on ovarian reserve markers
Basal FSH variations after uni/bilateral salpingectomy
A total of twelve manuscripts reported evidence regard-
ing possible variations in FSH serum values following
uni/bilateral salpingectomy [8, 10, 16, 17, 20–23, 27–29,
31]. We analyzed data from 1,569 patients. A total of
676 (43.1 %) patients underwent uni/bilateral salpingec-
tomy, of these, 68.3 % (462 patients) underwent unilat-
eral salpingectomy and 20 % (135 patients) bilateral
salpingectomy. In a total of 79 (11.7 %) patients the
technique was unspecified. Only 5.5 % (86 women) of
patients underwent proximal tubal division, ligation or
occlusion. We excluded from data analysis 7 (0.5 %) pa-
tients from Uyar et al. [23] because they underwent
surgical procedures other than salpingectomy or tubal
division.
In particular, seven papers [10, 16, 17, 20, 27, 29, 31]
reported evidence from observational prospective studies
evaluating FSH serum value before and after uni/bilateral
salpingectomy. Six of these studies, including a total of
376 patients, did not report statistically significant dif-
ferences in terms of serum FSH changes before and
after surgical intervention [16, 17, 20, 27, 29, 31]. Only
Gelbaya et al. [10] reported a significant increase in
FSH after uni/bilateral salpingectomy in a total of 40
patients (detailed data are reported in Table 2).
The remaining five studies [8, 21–23, 28] were obser-
vational and reported evidence from the comparison of
patients treated by salpingectomy with untreated controls.
In particular, four manuscripts, considering a total of 290
patients treated by unilateral/bilateral salpingectomy vs.
266 controls (50 proximal tubal division/ligation/occlu-
sion, 56 sclero-therapy, 160 patients not treated surgically)
did not reveal statistically significant differences in terms
of serum FSH values [8, 21–23]. Only Ye et al. [28] re-
ported a significant increase in FSH levels in 124 patients
treated vs. 74 untreated controls (Table 2).
Basal AMH and AFC variations after uni/bilateral
salpingectomy
Concerning basal AFC and AMH values we reported evi-
dence from a total of nine studies [13, 18, 22, 23, 25–28,
31]. Four considered only basal AFC [13, 18, 23, 27], two
only AMH [25] and three considered a combination of
both parameters [22, 28, 31]. We analyzed data from
1,017 patients. A total of 510 (50.2 %) underwent uni/
Fig. 1 Study’ flow-chart according to PRISMA guidelines
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Table 1 Descriptive data of all eligible studies regarding patients, their general features, type and indication for surgery and type/duration of infertilityIncluded








BMI (± SD) Indication for
Surgery
Time from Surgery Reason of Infertility Duration of
Infertility




b) 73 no surgery
(healthy subjects)
a) 33.1 ± 4.9
b) 34.2 ± 4.1
n.r a) ECP 2 years a,b) MF 31; ID 42 2 years after
surgery at
least







a) 31.7 ± 4.5
b) 30.6 ± 3.3
n.r a,b) salpingitis
or HY
a) 10.1 ± 7.5 months
b) 9.5 ± 7.2 months
(LPS diagnostic)
a,b) TF a) 55.2 ±
33.3
months
b) 48 ± 25.4
months









n.r a) HY 92 pz between 1.5
and 5 years
47 pz 3–6 months
a,b) TF n.r




b) 88 no surgery
(TF, HY)
a) 31.8 ± 3.6
b) 31.8 ± 3.7
n.r a,b) HY uni o
bilateral
2 months (at least) a,b) TF 1 month to
2 years












a) MEF 16; MF 6
AN 1; END 1; ID 2
n.r







a) 32.7 ± 3.6 n.r a) HY n.r n.r n.r





b) 82 no surgery
(TF, HY)
a) 32.8 ± 3.5
b) 32.5 ± 3.8
n.r a) HY n.r a,b) TF n.r




b) 15 PTO (HY)
c) 35 no surgery (TF
no HY)
d) 12 tubal ligation
(prior sterilization)
a) 35.1 ± 0.7
b) 35.4 ± 1.0
c) 35.6 ± 0.7
d) 38.2 ± 1.0
n.r a,b) HY
c,d) TF
6 months a,b,c,d) TF n.r




b) 52 no surgery
(healthy subjects)
a) 32.1 ± 4.1
b) 32.0 ± 5.1













Table 1 Descriptive data of all eligible studies regarding patients, their general features, type and indication for surgery and type/duration of infertilityIncluded (Continued)











a,b) ECP 3 months (at least) n.r n.r
Kontoravdis et al. [9] RCT 115 a) 50 POT (HY)




c) 15 no surgery
(HY)
a) 31 ± 4.5
b) 29.8 ± 3.4













c) 103 no surgery
(tubal factor, no HY)
a) 32.8 ± 3.57
b) 33.1 ± 2.71
c) 33.5 ± 3.32
n.r a,b) HY 3 months at least All TF plus:
a) MF 2/40; OF 4/40;
END 2/40
b) MF 5/25;OF 5/25;
END 1/25
c) MF 12/103; OF 9/
103; END 5/103
n.r
Moshin & Hotineanu [11] RCT 204 a) 60 SLP (HY)





c) 66 no surgery
(HY)
n.r n.r a,b) HY n.r n.r n.r







a) 41.6 ± 1.7
b) 41.1 ± 1.4
a) 24.5 ± 2.2
b) 26.6 ± 4.8
n.r n.r n.r n.r






a) 31.7 ± 6.3
b) 35.3 ± 3.6
n.r a,b) HY n.r n.r n.r








a) 32 ± 4.4 24 ± 5.5 a) HY n.r n.r n.r








a) 34.2 ± 4.5 n.r a) ECP 21
HY 14
Both 1













Table 1 Descriptive data of all eligible studies regarding patients, their general features, type and indication for surgery and type/duration of infertilityIncluded (Continued)









b) 80 no surgery
(healthy subjects)












a) 32.4 ± 4.5
b) 32.9 ± 4.1
a) 22.2 ± 5.0
b) 21.5 ± 2.2
a, b) HY n.r a,b) HY a) 3.8 ± 3.4
b) 2.9 ± 1.8





d) 51 no surgery
(TF, no HY)
a) 29.23 ± 2.98
b) 30.12 ± 3.73
c) 30.65 ± 3.32
d) 29.18 ± 3.36
a) 21.21 ± 2.05
b) 21.37 ± 1.89
c) 20.78 ± 2.04
d) 20.95 ± 1.66




a) 2.00 ± 1.67
years
b) 3.14 ± 2.12
c) 4.61 ± 2.81
d) 3.98 ± 2.44






- 1 tubal milkink
- 1 fimbriectomy
- 2 tubal abortion
surgery: LPS/LPT
b) 49 MTX (ECP)
c) 80 no surgery
a) 31.1 ± 5.1
b) 29.7 ± 5.0
c) 28.9 ± 6.0
n.r a, b) ECP n.r n.r n.r
Lin et al. [24] R 288 cycles
in 251
women
a) 103 cycles in
96 SLP Type: not
specified
Surgery: LPS





a) 33.2 ± 4.2
b) 32.8 ± 4.6
a) 22.1 ± 4.3
b) 21.9 ± 3.2
a) ECP or HY n.a a,b) TF n.a





b) 42 no surgery
(TF, with or without
HY)



















a) 36.6 ± 4.5
b) 37.8 ± 5.0
a) 34.4 ± 6.8









a) 35.8 ± 4.3
b) 34.3 ± 4.5













Table 1 Descriptive data of all eligible studies regarding patients, their general features, type and indication for surgery and type/duration of infertilityIncluded (Continued)
Surgery: not
specified
b) 153 MTX (ECP)






c) 74 no surgery
(infertility, no TF)
a) 33,02 ± 4,66
b) 33,58 ± 3,95
c) 33,8 ± 4,67
a) 21,63 ± 2,46
b) 21,1 ± 2,85







n.r a) MF 45;
MF & FF 28
b) MF 16
MF & FF 15
c) MF 38
MF & FF 26
UNKNOWN 2
a) 0.31 ± 1.13
PI
2.85 ± 2.81 SI
b) 0.82 ± 1.96
PI
3.23 ± 3.24 SI
c) 3.6 ± 4.15
PI
2.36 ± 3.32 SI
Pereira et al. [29] R 144 a) 37 SLP (ECP)
Type: unilateral
Surgery: LPS




a) 36.4 ± 3.03
b) 37.1 ± 4.01
a) 24 ± 3.65
b) 23.2 ± 4.23
a,b) ECP 12 months a) A 31.8 %; TF 3
13.6 %; END 9 %; MF
18.1 %; ID 4.55 %;
Other 18.1 %
b) AN 32.9 %;TF
12.5 %: END 7.95 %;
MF 23.9 % ID 5.68 %
Other 15.9 %
n.r







a) 32.5 ± 3.93
b) 33.8 ± 3.07
a) 24.9 ± 4.5
b) 24 ± 3.76
a,b) ECP a) 3.11 ± 2.90 years
b) 6.85 ± 5.05 years
a) TF 92 (78 %)
a) other reasons 26
(22 %)
b) TF 24 (70.6 %)
b) other reason 10
(29.4 %)
n.r
Venturella et al. [31] RCT 186 a) 91 SLP
standard






a) 41.16 ± 5.33






SLP, salpingectomy; n.r, not reported; n.a, not applicable; ECP, ectopic pregnancy; HY, Hydrosalpinx; TOA, tubo-ovarian abscess; FF, female factor (n.s), TF, tubal factor; OF, ovarian factor; MF, male factor; END, Endomet-
riosis; MEF, mechanical factor; AN, anovulation; ID, idiopathic; R, retrospective; OP, observational-prospective; RCT, randomized controlled trial; P-CS, prospective cross-sectional study; PC, prospective cohort study; LPS,













Table 2 Ovarian reserve test (AMH and AFC) and basal-FSH of patients included in the review
OVARIAN RESERVE
Authors & Years Patients AMH ± SD p AFC ± SD/range p FSH ± SD/range p
Surrey et al. [8] a) 32 SLP (HY)
Type: not specified
b) 15 PTO (HY)
c) 35 no surgery (TF no HY)
d) 12 tubal ligation
n.r. n.r. a) 7.07 ± 0.12
b) 6.65 ± 0.42
c) 7.08 ± 0.23
d) 7.47 ± 0.25
ns
Chan et al. [13] 32 SLP (ECP)
a) 18 unilateral LPS
b) 14 unilateral LPT
n.r - Operated site








Gelbaya et al. [10] a) 40 SLP (HY)
Type: 16 unilateral, 24 bilateral
b) 25 PTD
Type: 9 unilateral, 16 bilateral
c) 103 no surgery
(tubal factor, no HY)
n.r - n.r - IU/L
a) 6.8 ± 1.3 pre
7.61 ± 2.31 post
b) 6.4 ± 1.5 pre
6.35 ± 1.51 post
c) 6.6 ± 2.3 pre




Sezik et al. [16] a) 12 total hysterectomy +
bilateral SLP
b) 12 total hysterectomy without
SLP
n.r - n.r - a) Basal 4.8 ± 1.4
1 month 4.2 ± 1.6
6 months 4.4 ± 2.1
b) Basal 5.9 ± 1.6
1 month 5.2 ± 1.6
6 months 5.5 ± 1.2
ns
Nakagawa et al. [17] a) 6 SLP (HY)
Type: not specified
b) 11 PTD (HY)
n.r - n.r - IU/L
Before surgery
a) 8.0 ± 2.9
b) 6.8 ± 1.1
After surgery
a) 8.6 ± 4.0
b) 14.1 ± 9.3
a) ns
b) ns
Orvieto et al. [18] a) 15 uni/bilateral SLP
(HY)
n.r - Before surgery
a) 5.6 ± 2.5
affected side
11.4 ± 4.5 both
side
After surgery
a) 4.7 ± 2.3
affected side
9.5 ± 4.9 both
side
a) .05 n.r -
Xi et al. [20] a) 76 SLP (ECP)
- 44 unilateral
- 32 bilateral
b) 80 no surgery (healthy
subjects)
n.r - n.r - IU/L
Before surgery




a) 7.2 ± 1.6
7.3 ± 1.2
7.2 ± 1.4
b) 7.2 ± 1.8
a) ns
Na et al. [21] a) 41 SLP (HY)
Type: not specified
b) 56 sclerotherapy (HY)
n.r - n.r - IU/L
a) 8.2 ± 4.6
b) 10.9 ± 17.1
ns
Grynnerup et al. [25] a) 16 SLP (HY)
Type: not specified
b) 42 no surgery (TF, with or
without HY)









n.r - n.r -
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bilateral salpingectomy; of these, 75.1 % (383 patients),
underwent unilateral salpingectomy, 18.8 % (96 patients)
bilateral salpingectomy and 6.1 % (31 patients) unspecified
procedures. Only 23 (2.3 %) patients underwent tubal div-
ision. Three manuscripts, for a total of 237 (23.3 % of the
sample) patients, defined the control group as the same
cohort of patients prior to undergoing surgery [18, 27, 31].
Four manuscripts defined the control group as either un-
treated patients, for a total of 260 (25.6 %) or patients
treated by methotrexate (MTX) for ectopic pregnancy, for
a total of 202 (19.9 %) [22, 23, 25, 28]. Chan et al. [13]
defined as the control group for AFC count, the counter-
lateral adnexa of the same group of patients treated by
unilateral salpingectomy. Findley et al. [26] established as
control group patients subjected to total hysterectomy
without salpingectomy. We excluded from data analysis 7
(0.7 %) patients from Uyar et al. [23] because they under-
went surgical procedures other than salpingectomy or
tubal division.
In three studies [18, 27, 31], the variation in basal
AFC before and after unilateral/bilateral salpingectomy
in the same cohort of patients was evaluated. Two,
reporting evidence derived from observation of 222
patients, did not observe statistically significant differ-
ences in terms of AFC after unilateral salpingectomy
[27, 31]. Only one paper evaluating a total of 15 cases
of uni/bilateral salpingectomy reported a significant
decrease in AFC [18]. Three manuscripts reported
evidence from observational studies comparing patients
surgically treated versus controls (no-treated or medic-
ally MTX) In a total of 210 patients who underwent
uni/bilateral salpingectomy compared to 49 patients
treated by MTX for ectopic pregnancy, 23 patients who
underwent tubal division and finally 205 not untreated
patients, the three Authors did not observe any statisti-
cally significant decrease in AFC [22, 23, 28]. Only
Chan et al. [13] noted significant differences in a cohort
of 32 patients treated by unilateral laparoscopic and
Table 2 Ovarian reserve test (AMH and AFC) and basal-FSH of patients included in the review (Continued)
Uyar et al. [23] a) 33 patients (ECP)
- 26 unilateral SLP
- 3 salpingostomy
b) 49 MTX (ECP)
c) 80 no surgery
n.r - a) 10.1 ± 3.5
b) 10.3 ± 4.1





a) 7.7 ± 3.8
b) 7.7 ± 2.3




Ni et al. [22] 60 SLP (ECP, HY)
a) 26 bilateral
b) 34 unilateral
c) 23 PTO (HY)




















a) 7.35 ± 1.59
b) 7.17 ± 1.16
c) 7.64 ± 2.10





Findley et al. [26] a) 15 hysterectomy + bilateral SLP
b) 15 hysterectomy with no SLP
a) Basal 2.26 ± 2.72
4–6 weeks 1.03 ± 1.04
3 months 1.86 ± 1.99
b) Basal 2.25 ± 2.57
4–6 weeks 1.25 ± 2.09
3 months 1.82 ± 3.12
ns n.r - n.r -
Hill et al. [27] a) 36 SLP (ECP)
Type: unilateral
b) 153 MTX (ECP)
n.r - a) 10 (3–50) pre
10 (4–45) post





a) 7.2 (2.6 -16.0) pre
7.9 (5.1-10.4) post




Pereira et al. [29] a) 37 SLP (ECP)
Type: unilateral
b) 107 MTX (ECP)
n.r - n.r - mIU/mL
a) 4.98 ± 2.19 pre
4.87 ± 2.97 post
b) 4.81 ± 2.75 pre
4.94 ± 2.05 post
a) ns
b) ns
Ye et al. [28] 124 SLP (HY, ECP, TOA)
a) 83 unilateral
b) 41 bilateral
c) 74 no surgery (infertility, no TF)
fmol/mL
a) 167,56 ± 127,03
b) 127,11 ± 93,23
c) 183.48 ± 104,37
.05 a) 10,7 ± 3,62
b) 9,58 ± 3,73
c) 11,2 ± 4,16
ns mIU/mL
a) 8.42 ± 2.3
b) 9.13 ± 3.2
c) 7.85 ± 2.69
.05
Venturella et al. [31] a) 91 SLP standard




a) 0.93 ± 1.13
b) 0.86 ± 1.01
Δ After surgery
a) -0.09 ± 0.24 (Δ)




a) 7.8 ± 4.23
b) 6.82 ± 4.68
Δ After surgery
a) -0.33 ± 0.73 (Δ)






a) 12.9 ± 9.71
b) 12.39 ± 7.88
After surgery
a) 0.47 ± 0.86
b) 0.37 ± 0.84
a) ns
b) ns
n.r, not reported; ns, not significant; LPS, laparoscopy; LPT, laparotomy; MTX, methotrexate; PTD, proximal tubal division; PTO, Proximal tubal occlusion; ° On 21
patients (23 contro-lateral ligation excluded)
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a) 29 SLP (ECP)
Type: unilateral
b) 73 no surgery
(healthy subjects)
pmol/L
a) 6.087 ± 2.889
b) 6.635 ± 2735
ns a) 12.3 ± 1.6
b) 13.1 ± 2.0
ns - General
a) 9.9 ± 5.3












n.r - a) 2.4 ± 0.5
b) 2.0 ± 0.7





a) 30 SLP (HY)
Type: not specified





ns n.r - a) 10.1 ± 5.0
b) 10.5 ± 6.0
ns a) 5.2 ± 3.4
b) 4.8 ± 3.7
























a) 139 SLP (HY)
Type: 128 bilateral, 11
partial
b) 139 no surgery
(TF, no HY)
n.r - n.r - a) 9.3
b) 9.1




ns a) 40.3 (106)
b) 40.5 (120)





a) 116 SLP (HY)
Type: not specified
b) 88 no surgery
(TF, HY)
n.r - a) 11.4 ± 2.2
b) 11.6 ± 2.9
ns a) 10.6 ± 5.9
b) 10.6 ± 6.1
ns a) 6.8 ± 4.8
b) 7.0 ± 4.9
ns a) 2.0 ± 0.3
b) 2.0 ± 0.4












.05 a) 28.6 (32)
b) 16.3 (15)
.05
Dar et al. [5] a) 26 SLP (ECP)




n.r - Before surgery
a) 10.81 ± 2.45
After Surgery
a) 10.68 ± 2.57
ns Before surgery






a) - Operated site
5.31 ± 4.22
- Non operated
site 4.4 ± 3.68
ns n.r - Before surgery
a) 3.56 ± 0.81
After Surgery



























a) 26 SLP (general)
b) 9 unilateral
c) 17 bilateral
n.r - Before surgery
a) 11 ± 2.4
b) 12.2 ± 2.4
c) 10.4 ± 2.3
After Surgery
a) 11.2 ± 2.3
b) 12.2 ± 2.4
c) 10.6 ± 2.1
ns Before surgery
a) 9.4 ± 5.9
b) 9.1 ± 4.4
c) 9.5 ± 6.7
After Surgery
a) 8.7 ± 5.7
b) 7.7 ± 4.6
c) 9.2 ± 6.2
ns Before
surgery
a) 7.0 ± 5.6
b) 6.4 ± 3.9
c) 7.3 ± 6.5
After Surgery
a) 5.9 ± 4.3
b) 5.3 ± 4.3
c) 6.2 ± 4.4
ns n.r - n.r - n.r - n.r -
Strandell et
al. [7]
a) 103 SLP (HY)
Type: 40 unilateral, 63
bilateral
b) 82 no surgery
(TF, HY)
n.r - a) 11.3 ± 2.1
b) 11.4 ± 2.6
ns a) 10.3 ± 5.4
b) 10.6 ± 5.4
ns a) 6.8 ± 4.1
b) 7.1 ± 4.4
ns a) 2.0 ± 0.3
b) 2.0 ± 0.3








.05 HAZARD R (BR)
- Total group 2.1






a) 32 SLP (HY)
Type: not specified
b) 15 PTO (HY)
c) 35 no surgery (TF
no HY)
d) 12 PTO (prior
sterilization)
pg/mL
a) 2.555 ± 219
b) 2.366 ± 282
c) 2.925 ± 259
d) 2.479 ± 281
ns a) 9.5 ± 0.2
b) 10.1 ± 0.4
c) 9.8 ± 0.2
d) 9.3 ± 0.3
ns a) 16.2 ± 1.2
b) 14.4 ± 1.8
c) 17.5 ± 1.8
d) 12.2 ± 1.3
ns n.r a) 2.79 ± 0.2
b) 3.5 ± 0.4
c) 3.2 ± 0.2
d) 3.0 ± 0.3











a) 26 SLP (ECP)
Type: unilateral
b) 52 no surgery
(healthy subjects)
pmol /L
a) 5189 ± 3310
b) 5631 ± 3512
ns a) 11.6 ± 3.1
b) 10.8 ± 2.5
ns a) 8.6 ± 5.3
b) 8.4 ± 4.9
ns a) 5.5 ± 3.4
b) 4.0 ± 2.3
ns n.r - n.r - n.r - n.r -
Gelbaya et
al. [10]
a) 40 SLP (HY)
Type: 16 unilateral, 24
bilateral
b) 25 PTD
Type: 9 unilateral, 16
bilateral









.05 a) 10.35 ± 1.92
b) 10.28 ± 1.02
c) 10.17 ± 1.37
ns a) 10.23 ± 6.08
b) 13.68 ± 5.17





a) 6.78 ± 4.58
b) 8.52 ± 4.75
c) 7.80 ± 5.48

















a) 60 SLP (HY)
b) 78 POT (HY)
c) 66 no surgery (HY)
type: not specified
n.r - n.r - a) 10.4 ± 6.0
b) 10.2 ± 5.7
c) 9.8 ± 5.5
ns a) 7.0 ± 4.7
b) 6.9 ± 4.6
c) 6.8 ± 4.6
ns a) 3.4 ± 1.2
b) 3.4 ± 1.3
c) 3.5 ± 1.3









a) 50 POT (HY)
b) 50 SLP (HY)
c) 15 no surgery (HY)
type: not specified
n.r. - a) 12.3 ± 2.4
b) 11.9 ± 2.5
c) 13 ± 1.9
ns a) 11.6 ± 4.9
b) 12.1 ± 5.0
c) 10.9 ± 5.1
ns a) 8.7 ± 3.9
b) 8.53 ± 4.0
c) 7.9 ± 5.1
ns a) 2.6 ± 0.6
b) 2.6 ± 0.6








































Table 3 IVF outcome of patients included in the review (Continued)
Nakagawa
et al. [17]
a) 11 PTD (HY)
b) 6 SLP (HY)
type: not specified
pg/mL
a) 1553 ± 1468
b) 1530 ± 896
ns n.r - a) 5.3 ± 4.7
b) 7.5 ± 5.5













a) 1899.9 ± 185
After Surgery
a) 1997 ± 231
ns Before surgery
a) 10.5 ± 0.6
After Surgery
a) 10.4 ± 0.4
ns Before surgery
a) 10.2 ± 6.6
After Surgery
a) 10.3 ± 7.4








a) 1,996 ± 885
b) 2,020 ± 981
ns b) 10.5 ± 1.7
a) 10.8 ± 1.5
ns a) 11.6 ± 5.9
b) 10.2 ± 6.1
ns n.r - a) 2.7 ± 1.1
b) 2.3 ± 0.7
ns a) 6.7 (1/15)
b) 40 (6/15)
.05 n.r -


























a) 11.1 ± 1.8
11 ± 1.3
10.8 ± 1.9
b) 11.1 ± 1.8
ns Before surgery




a) 11.6 ± 4.1
11.1 ± 4.3
11.9 ± 5.5
b) 11.5 ± 4.4
ns Before
surgery




a) 8.4 ± 3.9
8.4 ± 4.0
8.4 ± 3.4
b) 8.0 ± 3.1






n.r - n.r - a) 6.2 ± 1.0
b) 12.1 ± 11











a) 2153 ± 1239
b) 2340 ± 1529
ns a) 8.8 ± 1.4
b) 8.8 ± 1.5
ns a) 7.4 ± 3.9
b) 7.6 ± 4.1
ns n.r - a) 2.5 ± 0.8
b) 2.5 ± 0.8








ns a) 30.3 (30/99)
b) 25.4 (45/77)
ns
Ni et al. [22] a) 26 bilateral SLP
b) 34 unilateral SLP
c) 23 PTO
d) no surgery (TF, no
HY)
n.r - a) 8.15 ± 1.29
b) 8.21 ± 1.27
c) 8.83 ± 1.37
d) 8.18 ± 1.35
ns a) 9.15 ± 3.73
b) 11.59 ± 6.14
c) 10.70 ± 4.92
d) 10.82 ± 4.82
ns a) 6.04 ± 2.85
b) 7.74 ± 4.23
c) 7.22 ± 3.25
d) 7.57 ± 3.74
ns a) 1.96 ± 0.45
b) 2.03 ± 0.39
c) 2.0 ± 0.43
d) 1.96 ± 0.20






















a) 16 SLP (HY)
Type: (uni/bilateral)
not specified
b) 42 no surgery (TF,
with or without HY)
c) 13 no surgery
(unexplained infertility,
no HY)








n.r - a) 2 (1–3)
b) 2 (1–2)
c) 2 (1–2)
























n.r - n.r - a) - 13 (3–31)
- 12 (3–31)
b) - 14 (2–36)
- 14 (0–35)
ns n.r - n.r - n.r - a) 14 (39)
b) 68 (44)





a) 107MTX (ECP) → 88
IVF
b) 37 unilateral SLP
(ECP) → 22 IVF
n.r - a) MTX
pre 9.55 ± 1.99
post 9.76 ± 2.33
b) SLP
pre 9.63 ± 2.21

















n.r - a) MTX
pre 2.92 ± 1.24
post 2.95 ± 1.38
b) SLP
pre 2.86 ± 1.19











Ye et al. [28] a) 83 unilateral SLP
b) 41 bilateral SLP
c) 74 no surgery
pg/mL
a) 38.3 ± 14.91
b) 41.41 ± 16.59
c) 36.49 ± 16.77
ns a) 9.6 ± 1.76
b) 9.39 ± 2.12
c) 9.78 ± 1.62
ns a) 7.83 ± 4.16
b) 6.98 ± 4.15
c) 8.42 ± 4.04
ns a) 3.39 ± 3.03
b) 3.15 ± 2.51
c) 3.5 ± 2.6
ns n.r - n.r - n.r - n.r -
Odesjo et
al. [30]
a) 118 unilateral SLP
b) 35 unilateral
salpingotomy
n.r - n.r - a) 11.69 ± 5.59
b) 11.8 ± 6.1
ns n.r - a) 104 (88 %)
b) 30 (85.7 %)
ns n.r - a) 32
(27.1 %)





SLP, salpingectomy; n.r, not reported; n.s, not significant; ECP, ectopic pregnancy; HY, Hydrosalpinx; ECP, ectopic pregnancy; TOA, tubo-ovarian abscess; TF, tubal factor; LPS, laparoscopy; LPT, laparotomy; PTD, proximal













laparotomy salpingectomy with the non-treated site in
the same cohort assigned as controls.
Concerning AMH serum values after uni/bilateral
salpingectomy a single manuscript reported evidence
evaluating AMH before and after the surgical procedure
in the same cohort of patients. Venturella et al. [31], in a
sample of 91 and 95 patients treated by unilateral salpin-
gectomy using standard and wide excision approach
respectively, did not observe statistically significant
differences in terms of decrease in AMH prior to and
3 months after surgical intervention. Three papers [22,
25, 28] reported evidence from observational studies
comparing surgically treated patients versus controls.
Two of the above mentioned papers compared a total of
76 cases of uni/bilateral salpingectomy versus 23 tubal
ligations versus 106 non surgically treated patients
and found no significant difference in terms of AMH
[22, 25]. Only one paper comparing a total of 124 cases
of uni/bilateral salpingectomy and 74 untreated controls
found a significant decrease in AMH value in the treated
group [28]. Finally, Findley et al. [26] in a cohort of 30
patients undergoing total hysterectomy (15 bilateral
salpingectomies vs. 15 untreated patients) did not find
significant differences in terms of AMH decrease neither
within the same group, nor between the two study
groups
Ovarian reserve markers after unilateral vs. bilateral
salpingectomy
Only three papers [20, 22, 28] evaluated the impact of
the type of surgical procedure by comparing unilateral
vs. bilateral salpingectomy. Ni et al. [22] comparing 26
bilateral salpingectomies, 34 unilateral salpingectomies
and 51 untreated controls found no significant differ-
ences, although in the bilateral salpingectomy group, a
slightly inferior AMH in terms of absolute value was
observed. Also Xi et al. [20] in an observational study
which considered exclusively FSH levels (44 unilateral
vs. 32 bilateral salpingectomy before and after surgery,
and 80 untreated controls) observed no significant
differences between groups. On the contrary, Ye et al.
[28], analyzed 83 unilateral vs. 41 bilateral salpingectomy
and 74 untreated patients, and found a significant de-
crease in both AMH and AFC and a significant increase
in FSH in treated patients. This trend was markedly pro-
nounced in patients treated by bilateral salpingectomy.
Effects on ART outcomes
A total of 24 studies for a total of 3001 patients have
reported data on the effects of salpingectomy on ART
outcomes. Of these 1,334 were treated by uni/bilateral
salpingectomy, 519 (38.9 %) patients underwent unilateral
salpingectomy, 346 (25.94 %) bilateral salpingectomy and
469 (35.16 %) unspecified. The principal indication for the
surgery was a previous ectopic pregnancy/ies and hydro-
salpinx in 7 [1, 5, 12, 20, 27, 29, 30] and 13 studies [2–4,
6–11, 17, 18, 21, 25], respectively. In 4 studies, both pa-
tients treated for ectopic pregnancy and hydrosalpinx
were included in the analysis [19, 22, 24, 28].
Length of stimulation
All 16 papers which analyzed the length of stimulation,
defined as number of days of gonadotropin administra-
tion, found a non-statistically significant different between
salpingectomy vs. non-salpingectomy patients [1–10, 12,
18–20, 28, 29].
E2 levels
Plasmatic E2 levels on the day of human chorionic gonado-
tropin (hCG) administration (for ovulation triggering) re-
sulted nonsignificant different between salpingectomy and
non-salpingectomy arms in 10 studies [1, 2, 8, 12, 17–20,
24, 28]. In only one retrospective analysis, including 40
patients treated by salpingectomy due to hydrosalpinx
compared to 103 patients with tubal factor infertility
(no hydrosalpinx), reported a significant reduction in
E2 levels in the salpingectomy group [10].
Oocytes retrieved
A total of 21 studies described the absence of any signifi-
cant difference in terms of number of oocytes retrieved
between salpingectomy and non-salpingectomy patients
or in pre and post-surgical procedure in the same cohort
of women [2–4, 6–12, 17–22, 24, 27, 28, 30]. Lass et al.
[1] compared 29 patients treated by salpingectomy for
ectopic pregnancy to 73 healthy women reporting a sig-
nificant reduction in oocyte yield in the ipsilateral com-
pared to the contralateral ovary. Grynnerup et al. [25]
compared a total of 16 cases of hydrosalpinx treated by
salpingectomy compared to 42 patients affected by tubal
factor infertility (with or without hydrosalpinx) managed
conservatively. A significant reduction of oocyte yield in
the treated group was observed [25].
Embryos obtained and/or transferred
All 11 [2, 4, 6, 7, 9–12, 20, 22, 28] and 14 [1, 3–5, 7–9, 11,
18, 22, 24, 25, 29, 30] studies which analyzed, respectively,
the number of embryos obtained and of embryos trans-
ferred found no statistically significant difference between
salpingectomy and non-salpingectomy patients.
Implantation rate
Only 6 studies assessed the implantation rate after IVF
and embryo transfer. Two randomized controlled trials
(RCTs) which compared patients with HY treated surgi-
cally or conservatively before IVF clearly demonstrated
a significant improvement in implantation rates [4, 9].
This improvement is even more prominent in ultrasound
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visible hydrosalpinx [4]. One RCT and one retrospective
study found no significant differences between treated and
untreated women, even if surgically treated patients for
hydrosalpinx showed a better implantation rate in terms
of absolute value compared to untreated subjects [2, 10].
Two further retrospective studies found no significant im-
provement of implantation rate in patients after salpingec-
tomy; however, in these cases, the control subjects were
represented by patients with tubal factor infertility without
hydrosalpinx [3, 24].
Clinical pregnancy rate
Clinical pregnancy rate was reported as outcome meas-
ure in 16 studies. In particular, five RCTs compared a
total of 359 patients affected by hydrosalpinx treated by
salpingectomy vs. 281 untreated control subjects [2, 4,
7, 9, 11]. Four of these studies reported a clear signifi-
cant improvement in the pregnancy rate of treated vs.
untreated subjects [4, 7, 9, 11]. The remaining RCT did
not show a significant improvement in pregnancy rate,
even if a better result in terms of absolute value for
transfer cycle in the salpingectomy group was reported
[2]. All other observational and retrospective studies,
with the exception of that reported by Orvieto et al. [18],
did not report differences in terms of pregnancy rate in
the salpingectomy compared to the control group; how-
ever, patients in the control group were generally affected
by infertility for tubal factor without hydrosalpinx or
were patients who underwent a surgical or medical pro-
cedure other than salpingectomy [1, 3, 8, 10, 17, 18, 21,
22, 24, 27, 30].
Ongoing pregnancy/live-birth rate
Data on ongoing pregnancy and the live-birth rates were
reported in 11 studies. Four RCTs compared a total 299
patients affected by hydrosalpinx treated by salpingec-
tomy vs. 215 untreated controls [2, 4, 7, 9]. In 3 of these
studies [4, 7, 9], a significant improvement in ongoing
pregnancy rate/live birth rate in treated vs. untreated
subjects was observed. A further RCT did not show
significant improvement of pregnancy rate, even if a
better result in terms of absolute value for transfer
cycle after salpingectomy was reported [2]. The other
available studies reported an improvement after salpin-
gectomy group; however, they were non-randomized
and poorly controlled. In fact, the controls were gener-
ally affected by infertility for tubal factor without
hydrosalpinx or were patients who underwent surgical
or medical procedures other than salpingectomy [3, 10,
22, 24, 27, 29, 30].
Discussion
During the past decades many debates have been raised
concerning the potential detrimental effects of hydrosalpinx
(both unilateral and bilateral) on implantation and preg-
nancy rate after ART [32]. Two meta-analyses, pub-
lished at the end of the nineties, were developed with
the aim to definitively clarify this topic. The first one,
analyzing more than 6,700 IVF cycles from 11 studies
demonstrated a pregnancy rate of less than 49 % and a
miscarriage rate 2–3 fold greater in patients with
hydrosalpinx compared to controls subjects with tubal
factor infertility without hydrosalpinx [odds ratio (OR
50.7), 95 % confidence interval (CI) 41.4 to 62.2) [33].
The second one, involving a total of 5,592 women (includ-
ing many of the same studies used in the first meta-
analysis), showed a delivery rate per cycle of 13.4 % vs.
23.4 % (OR 0.58, 95%CI 0.49 to 0.69) for hydrosalpinx
group and non- hydrosalpinx group, respectively [34].
In view of the above evidence it seemed logical to
propose surgery prior to ART in order to avert possible
deleterious effects derived from tubal fluids and conse-
quently increase their success rate [4]. Laparoscopic
unilateral or bilateral salpingectomy has been the first
and most studied surgical technique proposed. How-
ever, although several observational and retrospective
studies have been published, only five RCTs (of which
one published only in abstract form) concerning the
potential benefit of prophylactic laparoscopic salpingec-
tomy before ART in case of hydrosalpinx were con-
ducted. Despite potential bias due to small sample size
and lack of blind randomization, (see Table 1 for more
details) data analysis in all trials showed a clear advan-
tage in terms of implantation rate, pregnancy rate and
ongoing pregnancy rate in treated patients compared to
untreated controls [2, 4, 6, 7, 9, 11]. The derived data
encouraged the scientific community to recommend
tubal removal or tubal occlusion for hydrosalpinx prior
to ART [14, 15, 32, 35]. Though these recommenda-
tions may be of use in the management of evident
hydrosalpinx, controversy persists regarding the ideal
management of smaller unilateral or bilateral hydrosal-
pinx due to the potential detrimental effects of surgery
on the ovarian reserve. Analogous to the current trend
in surgical management of patients affected by ovarian
endometriomas [36, 37] tubal surgery before ART treat-
ments is an ongoing debate.
With the intent of proposing a solution to the current
dilemma, we analyzed several studies aimed at quantifying
possible damage on ovarian reserve caused by salpingec-
tomy. Considering data from operated vs. non-operated
site, almost all studies, with the exception of Dar’ data [5],
reported a significant reduction of AFC and number of
oocytes retrieved after ovarian stimulation limited to the
ipsilateral ovary [1, 13, 18, 25].
The pathophysiological explanation of this finding may
be related to two important phenomena: surgical dissec-
tion of vascular supply (mesosalpinx vessels) and energy
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spread by monopolar or bipolar devices [13, 18, 31, 38].
It is important to remember that AFC is only a surrogate
of ovarian reserve that should be interpreted ideally in
association with basal AMH, FSH and chronological age
[39–41]. Trials investigating variations in ovarian reserve
determined by the combination of both AFC and bio-
chemical assay of FSH and AMH levels seems to suggest a
non-significant reduction in the cohort of treated patients
compared to controls [8, 16, 17, 20–23, 25–27, 31].
This finding is likely affected by the bias of considering
unilateral salpingectomy (in which the damage may hap-
pen) while the estimated ovarian reserve considers both
ovaries. It is fundamental to understand the implications
of bilateral vs. unilateral salpingectomy on ovarian reserve
and potential response to controlled stimulation. Data re-
garding this last point are scarce and only three studies
analyzed this topic [20, 22, 28]. In only one study [28] a
significant decrease in AMH and an increase in FSH
serum values in the bilateral salpingectomy group was de-
tected, even if after ovarian stimulation there was no dif-
ference in the number of oocytes collected. Interestingly,
although all other Authors did not observe significant dif-
ferences, worse outcomes in terms of absolute value were
reported in bilateral salpingectomy group [22, 28].
Available data is scarce and does not clarify the issue
of the effect of potential additional damage caused by
bilateral as opposed to unilateral salpingectomy. The
lack of clear evidence does not permit speculation re-
garding the potential benefit of prophylactic salpingec-
tomy in patients undergoing ART and affected by
unilateral hydrosalpinx and contralateral or bilateral
tubal occlusion without hydrosalpinx. Certainly, if data
reported in the last trial by Venturella et al. [31] sug-
gesting no detrimental effect on ovarian reserve in
bilateral salpingectomy will be confirmed by further
trials, counselling for surgery in patients affected by
tubal occlusion (also in cases without hydrosalpinx)
may have a rationale and may result in further improve-
ments of ART success rates (avoiding implantation fail-
ure or even more important tubal pregnancy). Indeed,
when considering as outcome measure the implantation
rate, pregnancy rate and ongoing/live-birth rate after
ART in patients with hydrosalpinx, data from four
RCTs suggest distinct improvements in patients treated
by salpingectomy [4, 6, 7, 9, 11].
Infertile women affected by hydrosalpinx are at in-
creased risk for poor outcomes after IVF for a variety of
reasons linked to chronic subclinical infections, inflam-
mation and endometritis [42–44]. The pathophysiological
explanation may be related to the possible accumulation
of hydrosalpinx fluid within the endometrial cavity, which
may have detrimental effects on endometrial receptivity
and embryo development by a direct embryotoxic ef-
fect, mechanical washing of the blastocyst and by the
dilatational effect of hydrosalpinx fluids on essential nutri-
ents and fluids [45–52]. Moreover, although the data from
these RCTs would apparently put an end to the contro-
versy, the fact that the size and the localization (unilateral
versus bilateral) of the hydrosalpinx recommend caution
in the interpretation of data. The final aim of our review is
non only to offer an overview of available data on this
topic but to invite both scientists and clinicians in generat-
ing new data in order to finally clarify the role of salpin-
gectomy on ovarian reserve. Indeed, just as for example,
from our manuscript submission to final acceptance by
the journal, 2 meta-analysis have been published in a sin-
gle journal (August and October 2016) reporting opposite
results and potentially generating more confusion [53, 54].
Conclusions
From the analysis of all available literature it is possible to
conclude that in the presence of tubal disease a surgical
approach based on unilateral salpingectomy may be
considered safe and without negative effects on ovarian
reserve markers and on ovarian response to ovarian
stimulation protocols. Further trials aimed at confirming
both the positive effects of tubal surgery before ART and
the safety of bilateral salpingectomy are necessary to
definitively state when and why unilateral rather than
bilateral salpingectomy are recommended in cases of
bilateral tubal blockage with or without hydrosalpinx.
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